Literature DB >> 35814502

The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience.

Panita Mettikanont1, Anita Kalluri1, Therese Bittermann1, Neil Phillips1, Bao-Li Loza1, Mark Rosen1, Evan Siegelman1, Emma Furth1, Peter Abt1, Kim Olthoff1, Abraham Shaked1, Maarouf Hoteit1, K Rajender Reddy1.   

Abstract

Background and aims: The Liver Reporting and Data System (LI-RADS) is the standard classification of imaging findings of hepatic abnormalities for hepatocellular carcinoma (HCC) surveillance. We aimed to study the course of LI-RADS 3 and 4 (LR-3 and LR-4) abnormalities through correlations with explant pathology.
Methods: A single center retrospective study of liver transplant recipients between January 2016 and September 2019 with HCC on explant pathology was conducted. Eligible patients were divided into three subgroups based on their LI-RADS classification: LR-3/4, LR-5 only, and combination of LR-3/4/5.
Results: There were 116 eligible patients with 99 LR-3/4 observations (60 LR-3 and 39 LR-4); the rest had LR-5 lesions. LR-4 more often than LR-3 observations progressed to LR-5 (36% vs 12%) and with shorter duration during follow-up (median 175 days and 196 days). Mean size growth of LR-3 and LR-4 abnormalities were 2.6 and 3.8 mm; median growth rates were 0.2 and 0.4 mm/month, respectively. Numbers of HCC lesions per explant, largest HCC lesion size, and cumulative size were higher in LR-3/4/5 subgroup than LR-5 subgroup (P = 0.007, 0.007 and 0.006, respectively); 68% of LR-3 and 82% of LR-4 abnormalities were confirmed HCC on explant (P = 0.09).
Conclusion: Compared to LR-3, more LR-4 abnormalities progressed to LR-5 (12% and 36%, respectively) in a shorter time and with faster growth rate. A high proportion of LR-3 and LR-4 lesions (68% and 82%, respectively) were confirmed HCC on explant, raising the question of whether excluding HCC based on radiologic criteria alone is adequate in those with LR-3/4 abnormalities.
© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFP, alpha-fetoprotein; BMI, body mass index; CT, computed tomography; HBV, hepatitis b virus; HCC, hepatocellular carcinoma; HCV, hepatitis c virus; LI-RADS, liver reporting and data system; LIRADS classification; LR-3, LI-RADS 3; LR-4, LI-RADS4; LR-5, LI-RADS 5; LT, liver transplantation; MELD-Na, model for end stage liver disease sodium; MRI, magnetic resonance imaging; explant pathology; hepatocellular carcinoma; liver transplant

Year:  2022        PMID: 35814502      PMCID: PMC9257948          DOI: 10.1016/j.jceh.2022.02.005

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  33 in total

1.  CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis.

Authors:  Nam C Yu; Vinika Chaudhari; Steven S Raman; Charles Lassman; Myron J Tong; Ronald W Busuttil; David S K Lu
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

2.  CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

Authors:  Sunyoung Lee; Yeun-Yoon Kim; Jaeseung Shin; Shin Hye Hwang; Yun Ho Roh; Yong Eun Chung; Jin-Young Choi
Journal:  J Am Coll Radiol       Date:  2020-07-05       Impact factor: 5.532

3.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Authors:  Pierre-Alain Clavien; Mickael Lesurtel; Patrick M M Bossuyt; Gregory J Gores; Bernard Langer; Arnaud Perrier
Journal:  Lancet Oncol       Date:  2011-10-31       Impact factor: 41.316

4.  Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.

Authors:  Chae Jung Park; Chansik An; Sumi Park; Jin-Young Choi; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-10-23       Impact factor: 5.315

5.  The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.

Authors:  G Kong; C Jackson; D M Koh; V Lewington; B Sharma; G Brown; D Cunningham; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-18       Impact factor: 9.236

Review 6.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

7.  Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging.

Authors:  Masahiro Tanabe; Akihiko Kanki; Tanya Wolfson; Eduardo A C Costa; Adrija Mamidipalli; Marilia P F D Ferreira; Cynthia Santillan; Michael S Middleton; Anthony C Gamst; Yuko Kono; Alexander Kuo; Claude B Sirlin
Journal:  Radiology       Date:  2016-04-26       Impact factor: 11.105

8.  Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound.

Authors:  M Abd Alkhalik Basha; D Abd El Aziz El Sammak; A A El Sammak
Journal:  Clin Radiol       Date:  2017-06-30       Impact factor: 2.350

Review 9.  CT/MRI LI-RADS v2017 - review of the guidelines.

Authors:  Grzegorz Rosiak; Joanna Podgórska; Edyta Rosiak; Andrzej Cieszanowski
Journal:  Pol J Radiol       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.